We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04566393
Expanded Access Status : Available
First Posted : September 28, 2020
Last Update Posted : February 14, 2023
Cancer Commons
Information provided by (Responsible Party):

Tracking Information
First Submitted Date September 17, 2020
First Posted Date September 28, 2020
Last Update Posted Date February 14, 2023
Descriptive Information
Brief Title Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
Brief Summary The objective of this expanded access program is to provide ulixertinib (BVD-523) for compassionate use in advanced cancer patients with MAPK pathway-altered solid tumor(s), including but not limited to KRAS, NRAS, HRAS, BRAF, MEK, and ERK mutations who have incomplete response to or have exhausted available therapies.
Detailed Description Not Provided
Study Type Expanded Access
Expanded Access Type Intermediate-size Population
Intervention Drug: Ulixertinib (BVD-523)
Ulixertinib (BVD-523) is an oral, first-in-class ERK1/2 inhibitor
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Recruitment Information
Expanded Access Status Available
Contact: xCures Clinical Operations (707) 641-4475 expandedaccess@xcures.com
Listed Location Countries United States
Removed Location Countries  
Administrative Information
NCT Number NCT04566393
Current Responsible Party xCures
Original Responsible Party Same as current
Current Study Sponsor xCures
Original Study Sponsor Same as current
Collaborators Cancer Commons
Investigators Not Provided
PRS Account xCures
Verification Date November 2022